New Canine Study From Belhaven Biopharma Supports Dry Powder Nasal Epinephrine Delivery Solution
Presented at Respiratory Drug Delivery 2024, the Nasdepi Canine Study Indicates the Dry Powder Nasal Solution Provides a Faster and More Effective Treatment for Anaphylaxis...
Belhaven Biopharma Announces Groundbreaking Clinical Results for Nasdepi, the Revolutionary Nasal Dry Powder Epinephrine Product
News of the Successful Trial Comes Amid an Oversubscribed Investor Round and Preparation for Series A Financing Round Belhaven Biopharma, a leader in innovative treatments...
Belhaven Biopharma Achieves Significant Milestones in Advancing Nasdepi – a Revolutionary Nasal Dry Powder Epinephrine Product
Several key accomplishments completed to finish 2023 and create a strong foundation for 2024. Belhaven Biopharma, a pioneering force in the development of emergency-use epinephrine...